ERBB2 and breast carcinoma: More recently, additional HER2 antibodies such as pertuzumab, and trastuzumab chemotherapy conjugates such as trastuzumab emtansine and trastuzumab deruxtecan, have been added to the treatment algorithm for late and early stage HER2 positive breast cancer, increasing the use of HER2 antibodies in this breast cancer subtype.